# EDGAR Filing Document

**Accession Number:** 0001306830
**File Stem:** 0001306830-26-000017
**Filing Date:** 2026-2
**Character Count:** 125063
**Document Hash:** bb168f808a2ce8b01856d39acd723c1b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001306830-26-000017.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001306830-26-000017

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 32

**CONFORMED PERIOD OF REPORT**: 20260217

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celanese Corp
- **CENTRAL INDEX KEY:** 0001306830
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTIC MATERIAL, SYNTH RESIN/RUBBER, CELLULOS (NO GLASS) [2820]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 980420726
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32410
- **FILM NUMBER:** 26643072

**BUSINESS ADDRESS:**
- **STREET 1:** 222 W. LAS COLINAS BLVD., SUITE 900N
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039-5421
- **BUSINESS PHONE:** 972-443-4000

**MAIL ADDRESS:**
- **STREET 1:** 222 W. LAS COLINAS BLVD., SUITE 900N
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039-5421

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Celanese CORP
- **DATE OF NAME CHANGE:** 20041102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Blackstone Crystal Holdings Capital Partners (Cayman) IV Ltd.
- **DATE OF NAME CHANGE:** 20041022

?xml version='1.0' encoding='ASCII'? ce-20260217

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 17, 2026

**CELANESE CORPORATION** 

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-32410** | **98-0420726** |
| (State or other jurisdiction<br>of incorporation) | (Commission File<br>Number) | (IRS Employer<br>Identification No.) |

---

**222 West Las Colinas Blvd. Suite 900N, Irving, TX 75039**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(972) 443-4000** 

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of Each Class</u>** | **<u>Trading Symbol(s)</u>** |  **<u>Name of Each Exchange on Which Registered</u>** |
| **Common Stock, par value $0.0001 per share** | **CE** | **The New York Stock Exchange** |
| **4.777% Senior Notes due 2026** | **CE /26A** | **The New York Stock Exchange** |
| **2.125% Senior Notes due 2027** | **CE /27** | **The New York Stock Exchange** |
| **0.625% Senior Notes due 2028** | **CE /28** | **The New York Stock Exchange** |
| **5.337% Senior Notes due 2029** | **CE /29A** | **The New York Stock Exchange** |
| **5.000% Senior Notes due 2031** | **CE /31** | **The New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure**

On February 18, 2026, Scott A. Richardson, President, Chief Executive Officer and Director of Celanese Corporation (the "<u>Company</u>"), will make a presentation to investors and analysts via a webcast hosted by the Company at 9:00 a.m. ET (8:00 a.m. CT) regarding the Company's financial results for its fourth quarter and full year 2025. The webcast, press release, prepared remarks from management and a slide presentation may be accessed on our website at <u>investors.celanese.com</u> under News & Events / Events Calendar. A copy of the prepared remarks and a copy of the slide presentation posted for the webcast are attached to this Current Report on Form 8-K ("<u>Current Report</u>") as Exhibit 99.1(a) and Exhibit 99.1(b), respectively, and are incorporated herein solely for purposes of this Item 7.01 disclosure. During the webcast, management may make, and management's prepared remarks and the attached slide presentation contain, references to certain Non-US GAAP financial measures. Non-US GAAP financial measures appearing in management's prepared remarks are defined and reconciled to the most comparable US GAAP financial measure in our Non-US GAAP Financial Measures and Supplemental Information document furnished with this Current Report as Exhibit 99.2 (and available on our website) and incorporated herein solely for purposes of this Item 7.01 disclosure.

**Item 9.01 Financial Statements and Exhibits**

(d) The following exhibits are being furnished herewith:

---

| | |
|:---|:---|
| **Exhibit<br>Number** | |
| **Exhibit<br>Number** |<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Description** |
| 99.1(a) | <u>[Prepared Remarks from Management dated](q420258-kex991a.htm)[February](q420258-kex991a.htm)[17](q420258-kex991a.htm)[, 202](q420258-kex991a.htm)[6](q420258-kex991a.htm)[\*](q420258-kex991a.htm)</u> |
| 99.1(b) | <u>[Slide Presentation dated February 17, 2026\*](q420258-kex991b.htm)</u> |
| 99.2 | <u>[Non-US GAAP Financial Measures and Supplemental Information dated](q420258-kex992.htm)[February](q420258-kex992.htm)[1](q420258-kex992.htm)[7](q420258-kex992.htm)[, 202](q420258-kex992.htm)[6](q420258-kex992.htm)[\*](q420258-kex992.htm)</u> |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document contained in Exhibit 101) |

---

\* In connection with the disclosure set forth in Item 7.01, the information in this Current Report, including the exhibits attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), or otherwise subject to the liabilities of such section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **CELANESE CORPORATION** | **CELANESE CORPORATION** |
| By: | /s/ ASHLEY B. DUFFIE |
| Name: | Ashley B. Duffie |
| Title: | Senior Vice President, General Counsel and Corporate Secretary |
| Date: | February 17, 2026 |

---

## Exhibit 99.1

**Exhibit 99.1(a)**

![picture2a.jpg](picture2a.jpg)

**Fourth Quarter 2025 Earnings Prepared Comments**

**Bill Cunningham, Celanese Corporation, Vice President, Investor Relations**

This is the Celanese Corporation fourth quarter 2025 earnings prepared comments. The Celanese Corporation fourth quarter 2025 earnings release was distributed via Business Wire this afternoon and posted on our investor relations website, investors.celanese.com. As a reminder, some of the matters discussed below may include forward-looking statements concerning, for example, our future objectives and plans. Please note the cautionary language contained at the end of these comments. Also, some of the matters discussed include references to non-GAAP financial measures. Explanations of these measures and reconciliations to the comparable GAAP measures are included on our investor relations website under Financial Information/Non-GAAP Financial Measures. The earnings release and Non-GAAP information and the reconciliations are being furnished to the SEC in a Current Report on Form 8-K. These prepared comments are also being furnished to the SEC in a separate Current Report on Form 8-K.

On the earnings conference call tomorrow morning, management will be available to answer questions.

**Scott Richardson, Celanese Corporation, President and Chief Executive Officer**

Today, we reported full year 2025 adjusted earnings per share of $3.98 (inclusive of approximately $1.50 per share total Celanese transaction amortization<sup>1</sup>), and operating EBITDA of $1.9 billion. I am also pleased to report full year 2025 free cash flow of $773 million, representing an increase of more than 50 percent compared to 2024. These results reflect our action-oriented mind-set, disciplined execution, and focus on performance improvement, despite a continued challenging commercial backdrop compounded by geopolitical uncertainties.

Throughout the year, we executed against our key priorities of increasing cash flow to accelerate deleveraging, intensifying cost improvements, and driving top-line growth. Our teams consistently executed our action plans with rigor, driving significant achievements in 2025:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Generated strong free cash flow of over $750 million, which has been used for deleveraging.

<sup>1</sup> Calculated as intangible amortization from transactions divided by diluted weighted average shares outstanding.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Completed the Micromax<sup>®</sup> divestiture, and achieved approximately half of our targeted $1 billion of divestitures by the end of 2027.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Refinanced approximately $4 billion of debt and reduced maturities due in 2026 and 2027 from $4.8 billion to $2.1 billion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Realized over $120 million of cost reductions through multiple productivity programs initiated in the first quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced further footprint optimization actions, focused on high-cost sites, including closures in Sempach, Switzerland and Sarnia, Canada, and our intended closure in Lanaken, Belgium.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Delivered operating EBITDA margins above 20 percent in both Engineered Materials (EM) and the Acetyl Chain (AC), demonstrating resilience in the face of end-market headwinds.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Strengthened EM commercial performance by elevating pipeline quality and prioritizing value over volume, to drive mix enrichment across the portfolio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Streamlined EM business operations and reduced complexity while lowering inventory by more than $100 million.

2025 was a year of steady execution supporting our strategic priorities which do more than mitigate the difficult conditions experienced sector-wide. These achievements strengthen our foundation and position Celanese to capture meaningful opportunities as demand recovers. As we look ahead in 2026, we remain committed to advancing our three key priorities to deliver against several critical targets:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We are targeting $650 to $750 million of free cash flow in 2026. Also, we are advancing our divestiture efforts towards achieving the remaining half of our targeted $1 billion of divestitures by the end of 2027.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect to realize an additional $50 to $70 million of cost savings in 2026, bringing our total to nearly $200 million since the start of 2025. The main drivers are expected to be 1) approximately $10 million from actions executed in 2025; 2) approximately $30 to $50 million from continued execution of the multi-year EM complexity reduction program that was launched last year; and 3) approximately $10 to $20 million of plant productivity gains in the Acetyl Chain, including accelerated benefits tied to the intended Lanaken closure. We continue to prioritize manufacturing footprint actions to meet the contemporary needs of our businesses.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In addition, we plan to accelerate artificial intelligence (AI) adoption to drive efficiency, productivity, and growth in manufacturing operations and customer-facing activities. In April of 2025, we launched AskChemille.com, an innovative digital platform that enhances material selection for our customers. Additionally, we continue to advance our digital and AI capabilities in our manufacturing sites.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our focus remains on driving top-line growth and margin expansion through improved pipeline quality, mix enrichment, and value-based pricing.

Our progress to date reinforces our forward momentum and our commitment to further deleveraging in 2026 and beyond. We continue to build a stronger, more resilient Celanese, better positioned to deliver free cash flow and drive value creation through market cycles.

Today, we also reported fourth quarter 2025 adjusted earnings per share of $0.67 (inclusive of approximately $0.36 per share total Celanese transaction amortization<sup>2</sup>), as well as fourth quarter free cash flow of $160 million, enabling us to achieve our 2025 free cash flow target that we set at the outset of the year.

Similar to the previous quarter, our fourth quarter results benefited from favorable mix and slightly better than expected pricing in EM, as well as continued realization of our cost reduction initiatives. Volumes, which were challenged across both businesses, declined 7 percent sequentially driven by greater than expected seasonality and year-end destocking, as well as weakness in acetate tow. Additionally, earnings from Other Activities were unfavorable compared to expectations by approximately $10 million due to timing of incurred expenses.

Although our fourth quarter earnings results fell short of our expectations, we remain confident that we have the right plans in place to improve performance and drive long-term value creation. Our aggressive actions, combined with the fundamental strengths of our two leading business models, position us well in 2026 and beyond. We will continue to execute against our key priorities of increasing cash flow to accelerate deleveraging, intensifying cost improvements, and driving top-line growth.

Now, let me turn to the performance specifics of our businesses.

Engineered Materials generated fourth quarter adjusted EBIT of $183 million and operating EBITDA of $288 million at margins of 14 and 23 percent, respectively. EM's results were supported by continued execution of initiatives to reduce costs, enrich the sales mix, and drive value-based pricing. These efforts

<sup>2</sup> Calculated as intangible amortization from transactions divided by diluted weighted average shares outstanding.

------

collectively enabled adjusted EBIT margins to remain steady compared to the third quarter, despite a sequential net sales decrease of 8 percent that was driven by anticipated Western Hemisphere channel-partner destocking and lower than expected volumes in Asia.

For the full year 2025, EM delivered adjusted EBIT of $720 million and operating EBITDA of $1.2 billion at margins of 13 and 22 percent, respectively. The complexity reduction program, which launched in 2025, reduced costs and lowered inventories. We have also been refreshing and strengthening the EM operating model resulting in improved pipeline quality. Following the substantial first quarter automotive destocking, these initiatives largely steadied the business despite continual volume headwinds. Since the second quarter, EM averaged approximately $190 million of adjusted EBIT per quarter, excluding Micromax<sup>®</sup>, across the remainder of 2025, and year-over-year pricing largely stabilized.

In 2026, we will continue to reinforce the EM business operating model to drive near-term improvement and support future growth. To start, we are targeting an additional reduction of $80 to $100 million in working capital. We believe we can sustainably and effectively unlock cash from lower inventories while continuing to meet customer's needs.

As our complexity reduction program advances to its next phase, we are targeting $30 to $50 million of additional cost reductions in 2026. We meaningfully reduced our sales, general, and administrative (SG&A) expenses, and continue to take additional actions in 2026. In parallel, network optimization of our logistics and warehousing is also a key target for streamlining, efficiency, and savings in 2026.

The recent closing of the Micromax<sup>®</sup> transaction was a critical milestone marking progress toward our divestiture targets to drive debt reduction. We anticipate approximately $35 million of adjusted EBIT headwind related to this portfolio adjustment in 2026, which we expect to be largely offset by growth through commercialization of EM pipeline programs.

Continued improvement in pipeline quality and velocity remains key to fully leveraging EM's broad specialty product portfolio, deep material science application development expertise, as well as industry-leading capabilities in design and prototyping, computer aided engineering (CAE) simulation, and material processing. This focus advances our pipeline quality, which we measure by growth opportunity, margin expansion potential, and ability to win. As we've discussed previously, High Impact Programs are an important driver of improved pipeline attractiveness, bringing specialty products to high growth markets like electronics and data center componentry, drug delivery, electric vehicles, and performance apparel.

Another important step in the evolution of EM's commercial capabilities is the introduction of our digital assistant platform, AskChemille.com. By offering a comprehensive range of engineered material options,

------

Chemille™ transforms how design engineers access data for material selection and improve product designs. Platform interactions generate valuable data driven insights that Celanese engineers are already learning and benefiting from, giving us real-time insights into the evolving needs and preferences of our customers.

For the first quarter, we anticipate seasonal volume improvements in the Western Hemisphere, with partial volume offsets in Asia due to the extended Chinese New Year. We expect sequential improvement to product mix across most end-markets. We also anticipate a tailwind of approximately $30 million in the first quarter due to inventory builds related to a production campaign and the planned second quarter POM turnaround. Considering these factors, we expect EM adjusted EBIT for the first quarter to be $210 to $230 million and operating EBITDA to be $310 to $330 million.

The Acetyl Chain (AC) delivered fourth quarter adjusted EBIT of $146 million and operating EBITDA of $210 million, at margins of 16 and 22 percent, respectively. Net sales fell sequentially, driven by declines of 1 percent in price and 10 percent in volume. In the vinyls business, Western Hemisphere volumes weakened through the quarter as seasonal declines were greater than expected. In the acetate tow business, persistent competitive market dynamics contributed to lower sales and unfavorable mix, especially in Europe. Together, these accounted for approximately $25 million of headwinds to our expected quarterly results, offsetting the modest pricing favorability in acetic acid and VAM in Asia.

Before turning to a discussion of full year 2025, I'd like to provide an update regarding the recent weather event experienced in the United States. While Winter Storm Fern did cause a temporary shutdown of assets in affected areas, our teams had made preparations and were able to minimize the production losses. We have been working on multiple mitigation actions and do not anticipate significant earnings impacts as a result of the storm.

For the full year 2025, AC delivered adjusted EBIT of $695 million and operating EBITDA of $947 million at margins of 16 and 22 percent, respectively. While Eastern Hemisphere margins have been compressed by regional oversupply and weak demand, the larger challenges in 2025 for AC were Western Hemisphere demand and the overall dynamics in the acetate tow business. Weakness in key end-markets like paints, coatings, and construction fueled elevated competitive pressures and affected the vinyls business in the Western Hemisphere. As we've discussed previously, approximately 70 percent of AC's annual revenue has come from Western Hemisphere, and the proportion of variable margin contribution is even greater.

------

In the acetate tow business, 2025 was characterized by elevated competitive pressures and weaker demand conditions that challenged our volumes, pricing, and sales mix. Industry capacity additions in China came on-line during the year while customers were focused on right-sizing inventories. As a result, acetate tow accounted for the majority of the year-over-year AC variable margin decline. Much of the new capacity found available outlets in eastern Europe and southeast Asia, compressing our variable margins. These dynamics underscore the importance of our intended closure of the facility in Lanaken, which we expect to be completed in the second half of 2026. Implementing this strategic action demonstrates our proactive approach and commitment to reduce costs and enhance flexibility while continuing to meet customers' needs.

Looking to the first quarter, we expect modest seasonal recovery in the Western Hemisphere that will be partially offset by continued pressures in acetate tow. We anticipate an approximate $5 million headwind related to a planned turnaround of the methanol unit at Clear Lake. Also, similar to last year, the acetate tow dividend will be paid in three installments in 2026, starting in the second quarter, creating a sequential headwind in the first quarter of approximately $40 million. We anticipate the full year dividend to be consistent with last year. Considering these factors, we expect first quarter adjusted EBIT of $110 to $125 million, and operating EBITDA of $170 to $185 million.

Despite the continued macroeconomic challenges, we believe the agility and optionality inherent to the AC model will continue to drive productivity and capture opportunistic pockets of value. The AC team utilizes a two-pronged approach to offset end-market headwinds. The daily operating model enables agile response to market conditions to maximize earnings performance. Strategic initiatives strengthen the business foundation and expand operating leverage for future earnings growth. AC is deploying both sets of actions to drive earnings improvement. Such actions include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Accelerating benefits from the intended Lanaken site closure, with a target of $5 to $10 million of cost savings to be realized in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Dedicated plant productivity projects, targeting $5 to $10 million of additional cost savings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Continuing to idle the Frankfurt VAM unit through at least the first quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Continuing block operations of the Singapore unit in response to specific customer forecasts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Maximizing production at our lowest-cost gulf coast assets to drive profitability and reduce our cost-to-serve.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Driving growth in differentiated downstream applications to improve margins by leveraging chain optionality.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Accelerating commercialization of Eco-CC sustainable products, especially in coatings and adhesives, to increase differentiation and grow share of downstream applications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Accelerating deployment of manufacturing digitization tools through the AC production network.

These actions emphasize the fundamental advantages of the Acetyl Chain's business model that position AC well, especially when demand recovers.

**Chuck Kyrish, Celanese Corporation, Senior Vice President and Chief Financial Officer**

I would like to start by thanking our teams for advancing our strategic imperatives in 2025. As Scott highlighted, we delivered strong results across free cash flow generation, strategic divestitures, working capital reduction, opportunistic refinancing, and maintaining strong liquidity – actions that collectively reinforce the strength of our financial position.

In the fourth quarter, we capitalized on favorable debt market dynamics to execute a series of transactions to extend our debt maturity profile without adding meaningful incremental costs. Through these transactions, which included offerings of approximately $1.4 billion aggregate principal of notes, we reduced the combined value of our 2026 and 2027 debt maturities from $3.1 billion to $2.1 billion, aligning our near-term maturities to a conservative outlook for free cash flow generation and divestiture proceeds.

We closed 2025 with a strong liquidity position, including $1.3 billion in cash and $1.75 billion of undrawn revolver capacity. In February 2026, we bolstered this cash position by successfully completing the Micromax<sup>®</sup> divestiture, receiving $492 million in cash, subject to customary transaction adjustments, and further decreasing our net debt. This value-enhancing divestiture was signed and closed with rapid timing, and I want to thank our teams for their dedication through the process.

Before discussing our free cash flow performance, I would like to provide some commentary on our adjusted earnings. In Other Activities for the fourth quarter, we reported a net expense of $78 million in adjusted EBIT and $63 million in operating EBITDA. This was unfavorable versus our expectations by approximately $10 million, primarily due to the timing of recognition of certain expense items. Overall, net expense for Other Activities in 2025 were approximately 15 percent lower versus 2024 on an adjusted

------

EBIT basis, largely reflecting our numerous cost improvement actions. For 2026, we anticipate average quarterly net expense run rate of approximately $65 to $70 million in adjusted EBIT and $50 to $60 million in operating EBITDA, roughly consistent with 2025 levels.

Related to our adjusted earnings, the tax rate for U.S. GAAP purposes was 7 percent on a loss of $1.2 billion for the full year 2025 due to a book goodwill impairment charge of $1.1 billion for EM that did not provide a tax benefit and an increase in valuation allowance on U.S. foreign tax credit carryforward due to the revised forecasts of foreign-source income. These impacts were partially offset by deferred tax benefits related to integration transactions and realignment of intangibles and tax benefits related to the resolution of tax examinations. The effective tax rate for adjusted earnings for the full year 2025 is 8 percent excluding the impact of the goodwill charge that is non-deductible for tax purposes and other non-recurring items. We anticipate an effective tax rate for adjusted earnings in 2026 that is similar to 2025 absent any material changes in jurisdictional earnings mix.

Turning to free cash flow, we reported $160 million in free cash flow generation for the fourth quarter, bringing the full year 2025 free cash flow to $773 million. In a year marked by continued macroeconomic weakness, our teams demonstrated strong execution to deliver these results. This performance reflects the resilience of our differentiated business models and the discipline with which our teams execute.

Looking ahead to 2026, our visibility into demand conditions is limited at this point. However, I would like to point out a few items in free cash flow which will likely change year-over-year:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Working capital was a source of cash in 2025 of $393 million, which included $154 million of cash generation through inventory reduction as well as $213 million in accounts receivable reduction. While we do not expect this level of cash from working capital in 2026, we are targeting a minimum of $100 million of cash through continued working capital reduction efforts. Beyond this targeted structural improvement, the degree of working capital reduction across both businesses will be influenced by developments in the overall demand environment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• While net interest expense in the income statement will be roughly flat year-over-year, net cash interest paid in 2026 is expected to be approximately $50 million lower year-over-year, largely driven by accrued interest settlements related to the early retirement of tendered bonds in the fourth quarter, and timing of coupon payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash taxes for 2025 were $255 million, and expected to be lower by approximately $50 to $60 million in 2026, primarily reflecting lower anticipated settlements from prior year activity.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As Scott noted, our teams continue to refine and advance incremental cost reduction initiatives for 2026. At this stage, we anticipate cash outlay for cost reduction and restructuring initiatives in 2026 to be lower as compared to 2025 by roughly $25 to $50 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Capital expenditures for 2026 are expected to remain broadly consistent with 2025 levels of $300 to $350 million, as we continue to harvest the strategic capacity investments made over the past several years. Our focus will remain on safety, maintenance, regulatory and productivity projects, strengthening our ability to scale when external conditions improve.

Considering these factors, we are targeting free cash flow generation of approximately $650 to $750 million in 2026.

Our differentiated business models, combined with continued relentless execution of our action plans, give us confidence in the sustainability of Celanese's cash-generation capabilities. Deleveraging remains our top priority, and the actions we are taking not only drive meaningful near-term progress but also forge a strong foundation that will support and accelerate Celanese's long-term performance.

**Scott Richardson, Celanese Corporation, President and Chief Executive Officer**

Through the first six weeks of 2026, the macroeconomic backdrop has remained muted, and we expect first-quarter demand patterns to be similar to the fourth quarter. While we anticipate a modest seasonal recovery in Western Hemisphere volumes, we expect it to be partially offset by headwinds in Asia related to Chinese New Year. We also expect approximately $40 million of first-quarter impacts from the timing of the acetate tow dividend and from the turnaround of the methanol unit at Clear Lake. As a result, we anticipate first quarter adjusted earnings per share of approximately $0.70 to $0.85.

In 2026, we remain relentlessly focused on cash generation to further deleverage the balance sheet. As we streamline our businesses and refine plans to continue right-sizing our inventory levels, we anticipate some negative impacts to flow-through to reported earnings from actions we have taken and additional actions we plan to take. We are confident in our plans to drive another year of strong cash flow performance in 2026.

------

Our focus remains on driving controllable improvements across our businesses to help offset ongoing macroeconomic uncertainty. In addition to our plans to deliver $50 to $70 million in cost savings in 2026, our teams are working on evaluating additional opportunities, including additional manufacturing footprint optimization. In parallel, we expect to enhance our mix through higher-value growth opportunities and evolve our pipeline model to fully capitalize on our capabilities. We expect our growth initiatives to offset the earnings impact of the Micromax<sup>®</sup> divestiture as well as drive additional growth, assuming a steady demand environment.

Although we do not yet have sufficient visibility to provide a full-year outlook for 2026, we are confident in the actions underway to drive improvements for the year. We anticipate that the second quarter will represent the largest level of turnaround activity for the year, including the POM turnaround discussed earlier. Given this, and the timing of our cost reduction initiatives, it is likely that earnings improvements will be back-end weighted, positioning Celanese to benefit from a potentially more constructive operating environment in the third and fourth quarters.

We remain focused on self-help measures that are firmly within our control to combat the prolonged, industry-wide down cycle. Although timing is unclear, we are confident that the macroeconomic environment will improve over time. We are actively pursuing near-term, targeted tactics as well as bold transformational initiatives, and believe our decisive actions position Celanese to meaningfully benefit from the eventual recovery. The unique competitive advantages of our two business models provide substantial opportunities for earnings improvement and cash generation to support ongoing deleveraging. We remain confident that our disciplined execution and action orientation will continue to strengthen Celanese and support long-term, sustainable value creation.

I want to close by thanking our teams for their resilience, perseverance, and execution through this period. Their hard work has been critical to advancing our efforts as we build an even stronger Celanese for the long-term.

------

*Forward-Looking Statements*

*These prepared comments may contain "forward-looking statements," which include information concerning the Company's plans, objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capital expenditures, deleveraging efforts, planned cost reductions, dividend policy, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in these comments. These risks and uncertainties include, among other things: the ability to successfully achieve planned cost reductions; changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; the length and depth of product and industry business cycles, particularly in the automotive, electrical, textiles, electronics and construction industries;potential liability resulting from pending or future claims or litigation, including investigations or enforcement actions, or from changes in the laws, regulations or policies of governments or other governmental activities, in the countries in which we operate; our level of indebtedness and our financial condition, each of which could diminish our ability to raise additional capital to fund operations, reduce our business and strategic flexibility, increase our interest expense, limit the success of our deleveraging efforts, and impact changes to our credit ratings, which could increase our interest expense in the event of additional downgrades; volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp, hexamethylene diamine, Polyamide 66 ("PA66"), polybutylene terephthalate, ethanol, natural gas and fuel oil, and the prices for electricity and other energy sources; the ability to pass increases in raw materials prices, logistics costs and other costs on to customers or otherwise improve margins through price increases; the possibility that we will not be able to realize the anticipated benefits of the Mobility & Materials business (the "M&M Business") we acquired from DuPont de Nemours, Inc. (the "M&M Acquisition"), including synergies and growth opportunities, whether as a result of difficulties arising from the operation of the M&M Business or other unanticipated delays, costs, inefficiencies or liabilities; additional impairment of goodwill or intangible assets; increased commercial, legal or regulatory complexity of entering into, or expanding our exposure to, certain end markets and geographies; risks in the global economy and equity and credit markets and their potential impact on our ability to pay down debt in the future and/or refinance at suitable rates, in a timely manner, or at all; the ability to maintain plant utilization rates and to implement planned capacity additions, expansions and maintenance; the ability to reduce or maintain current levels of production costs and to improve productivity by implementing technological improvements to existing plants; increased price competition and the introduction of competing products by other companies; the ability to identify desirable potential acquisition or divestiture opportunities and to complete such transactions, including obtaining regulatory approvals, consistent with the Company's strategy; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, transportation, logistics or supply chain disruptions, cybersecurity incidents, AI-related vulnerabilities, terrorism or political unrest, public health crises, or other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the direct or indirect consequences of acts of war or conflict (such as the Russia-Ukraine conflict or conflicts in the Middle East) or terrorist incidents or as a result of fire, flood, hurricanes, other severe weather, natural disasters, other catastrophic events or other crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in applicable tariffs, duties, treaties and trade agreements, tax rates or legislation throughout the world including, but not limited to, anti-dumping and countervailing duties, adjustments, changes in estimates or interpretations or the resolution of tax examinations or audits that may impact recorded or future tax impacts and potential regulatory and legislative tax developments in the United States and other jurisdictions; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change or other sustainability matters; changes in currency exchange rates and interest rates; tax rates and changes thereto; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission.*

*Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.* 

*Results Unaudited*

*The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.*

*Certain prior period amounts have been revised to correct for certain prior period immaterial errors. See Note 1 to our Annual Report on Form 10-K for the annual period ending December 31, 2025.*

*Non-GAAP Financial Measures* 

*These prepared comments, and statements made in connection with these prepared comments, refer to Non-GAAP financial measures. For more information on the Non-GAAP financial measures used by the Company, including the most directly comparable GAAP financial measure for each Non-GAAP financial measure used, including definitions and reconciliations of the differences between such Non-GAAP financial measures and the comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, <u>investors.celanese.com</u>, under Financial Information/Financial Document Library.*

## Exhibit 99.1

![](q420258-kex991b001.jpg)

Q4 Investor Presentation Feb 2026

------

![](q420258-kex991b002.jpg)

Celanese Corporation Disclosures 2 Forward-Looking Statements This presentation may contain "forward-looking statements," which include information concerning Celanese Corporation's (the "Company") plans objectives, goals, strategies, future revenues, cash flow, financial performance, synergies, capital expenditures, deleveraging efforts, planned cost reductions, dividend policy, financing needs and other information that is not historical information. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the Company will realize these expectations or that these beliefs will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements contained in this presentation. These risks and uncertainties include, among other things: the ability to successfully achieve planned cost reductions; changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate; the length and depth of product and industry business cycles, particularly in the automotive, electrical, textiles, electronics and construction industries; potential liability resulting from pending or future claims or litigation, including investigations or enforcement actions, or from changes in the laws, regulations or policies of governments or other governmental activities, in the countries in which we operate; our level of indebtedness and our financial condition, each of which could diminish our ability to raise additional capital to fund operations, reduce our business and strategic flexibility, increase our interest expense, limit the success of our deleveraging efforts, and impact changes to our credit ratings, which could increase our interest expense in the event of additional downgrades; volatility or changes in the price and availability of raw materials and energy, particularly changes in the demand for, supply of, and market prices of ethylene, methanol, natural gas, carbon monoxide, wood pulp, hexamethylene diamine, Polyamide 66 ("PA66"), polybutylene terephthalate, ethanol, natural gas and fuel oil, and the prices for electricity and other energy sources; the ability to pass increases in raw materials prices, logistics costs and other costs on to customers or otherwise improve margins through price increases; the possibility that we will not be able to realize the anticipated benefits of the Mobility & Materials business (the "M&M Business") we acquired from DuPont de Nemours, Inc. (the "M&M Acquisition"), including synergies and growth opportunities, whether as a result of difficulties arising from the operation of the M&M Business or other unanticipated delays, costs, inefficiencies or liabilities; additional impairment of goodwill or intangible assets; increased commercial, legal or regulatory complexity of entering into, or expanding our exposure to, certain end markets and geographies; risks in the global economy and equity and credit markets and their potential impact on our ability to pay down debt in the future and/or refinance at suitable rates, in a timely manner, or at all; the ability to maintain plant utilization rates and to implement planned capacity additions, expansions and maintenance; the ability to reduce or maintain current levels of production costs and to improve productivity by implementing technological improvements to existing plants; increased price competition and the introduction of competing products by other companies; the ability to identify desirable potential acquisition or divestiture opportunities and to complete such transactions, including obtaining regulatory approvals, consistent with the Company's strategy; market acceptance of our products and technology; compliance and other costs and potential disruption or interruption of production or operations due to accidents, interruptions in sources of raw materials, transportation, logistics or supply chain disruptions, cybersecurity incidents, AI-related vulnerabilities, terrorism or political unrest, public health crises, or other unforeseen events or delays in construction or operation of facilities, including as a result of geopolitical conditions, the direct or indirect consequences of acts of war or conflict (such as the Russia- Ukraine conflict or conflicts in the Middle East) or terrorist incidents or as a result of fire, flood, hurricanes, other severe weather, natural disasters, other catastrophic events or other crises; the ability to obtain governmental approvals and to construct facilities on terms and schedules acceptable to the Company; changes in applicable tariffs, duties, treaties and trade agreements, tax rates or legislation throughout the world including, but not limited to, anti-dumping and countervailing duties, adjustments, changes in estimates or interpretations or the resolution of tax examinations or audits that may impact recorded or future tax impacts and potential regulatory and legislative tax developments in the United States and other jurisdictions; changes in the degree of intellectual property and other legal protection afforded to our products or technologies, or the theft of such intellectual property; potential liability for remedial actions and increased costs under existing or future environmental, health and safety regulations, including those relating to climate change or other sustainability matters; changes in currency exchange rates and interest rates; tax rates and changes thereto; and various other factors discussed from time to time in the Company's filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. Results Unaudited The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Historical results should not be taken as an indication of the results of operations to be reported for any future period. Pro forma financial information herein is preliminary and subject to change. Certain prior period amounts have been revised to correct for certain prior period immaterial errors. See Note 1 to our Annual Report on Form 10-K for the annual period ending December 31, 2025 Presentation This document presents the Company's two business segments, Engineered Materials and Acetyl Chain. Non-GAAP Financial Measures This presentation, and statements made in connection with this presentation, may refer to non-GAAP financial measures. For more information on the non-GAAP financial measures used by the Company, including the most directly comparable GAAP financial measure for each non-GAAP financial measures used, including definitions and reconciliations of the differences between such non-GAAP financial measures and the comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures.

------

![](q420258-kex991b003.jpg)

Discussion Topics 3 Earnings update Key actions and near- term imperatives

------

![](q420258-kex991b004.jpg)

Q4 2025 results and highlights Q4 2025 Results 4 Q4 2025 Highlights \* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures. Free Cash Flow\* ▪ Strong cash flow performance in Q4 ▪ Achieved FY2025 target range Engineered Materials (EM) ▪ Improved product mix driven by continued actions to strengthen pipeline quality ▪ Continued realization of targeted second half 2025 cost savings Acetyl Chain (AC) ▪ Operating EBITDA\* margins consistently above 20% for past five years ▪ Weaker dynamics in acetate tow and greater than expected vinyls seasonal declines in western hemisphere Q4 results reflect robust free cash flow\* generation, resilient EM performance, and continued focus on self-help measures $160 M FREE CASH FLOW\* $0.67 ADJUSTED EPS\* ADJUSTED EBIT\* BY BUSINESS SEGMENT $183 M ENGINEERED MATERIALS $146 M ACETYL CHAIN

------

![](q420258-kex991b005.jpg)

▪ Demand environment across most end-markets remains soft entering 2026 ▪ Seasonal volume recovery and continued mix enrichment in EM ▪ AC earnings expected to be impacted by timing of Tow dividend and maintenance at our methanol facility in Clear Lake, TX ▪ Ongoing focus to identify and implement actions to improve earnings Q1 2026 outlook Q1 2026 Outlook 5 Q1 2026 Focus Areas \* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures. Continued action orientation around cash generation and earnings improvement $0.70 - $0.85 ADJUSTED EPS\* GUIDANCE ADJUSTED EBIT\* GUIDANCE BY BUSINESS SEGMENT $210 M – $230 M ENGINEERED MATERIALS $110 M – $125 M ACETYL CHAIN

------

![](q420258-kex991b006.jpg)

Successfully executed series of actions in 2025 to advance Celanese priorities 6 ✓ Generated $773 million in free cash flow\* ✓ Completed refinancing of certain debt maturities ✓ Completed Micromax divestiture, proceeds planned for debt paydown to advance deleveraging ✓ Fully repaid balance on term loans aligned debt to currency of cash generation, lowering interest expense ✓ Reduced inventory in Engineered Materials by over $100 million ✓ Effectively renewed $1.75B revolving facility ✓ Realized $80 million in 2025 SG&A cost reductions in FY 2025 ✓ Delivered additional $40 million of cost improvement across business lines ✓ EM: further SG&A, network optimization ✓ AC: distribution cost reduction, block operating high-cost sites ✓ Announced further footprint optimization actions ✓ Sempach, Switzerland ✓ Sarnia, Canada ✓ Intention to close the facility at Lanaken, Belgium ✓ Operating EBITDA of $1.2 billion in EM and $950 million in AC ✓ 2025 Operating EBITDA margin of >20% in both AC and EM ✓ EM pipeline enrichment through focus on High Impact Programs INCREASE CASH FLOW INTENSIFY COST IMPROVEMENT DRIVE TOP LINE GROWTH \* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures.

------

![](q420258-kex991b007.jpg)

Celanese is committed to advancing initiatives in 2026+ that strengthen performance and create shareholder value 7 INCREASE CASH FLOW INTENSIFY COST IMPROVEMENT DRIVE TOP LINE GROWTH to deleverage the balance sheet through supercharging the pipeline & strategic opportunities by maximizing productivity every day Engineering Materials → Improve margins through improved pipeline quality → Cost reductions through SG&A and next wave of footprint optimizations → Multi-year, sustainable inventory reduction program Acetyl Chain → Maximize sales opportunities in downstream products → Drive productivity through low cost, U.S. based assets and strategic footprint actions → Leverage strength of the underlying operating model Cash And Earnings Growth → Relentless focus on cost reduction opportunities → Cash generation and divestitures for continued deleveraging → Opportunistic and prudent refinancing Continue to aggressively execute against key priorities

------

![](q420258-kex991b008.jpg)

Strong free cash flow\* execution in 2025; targeting sustained performance in 2026 in uncertain demand conditions 8 ✓ Free cash flow\* generation of $773 million in 2025 ✓ Targeting free cash flow\* generation of $650 to $750 million in FY2026 - Lower YoY working capital benefit + Lower YoY cash interest and cash taxes + Lower YoY cash for cost initiatives \* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures. Differentiated business models and focus on actions support sustainable cash generation capabilities 2024 2025 2026F $498 M ACTUALS ESTIMATE $773 M $650 - $750 M Free cash flow\* generation 2024 – 2026 ($M)

------

![](q420258-kex991b009.jpg)

2026 2027 2028 2029 2030 2031 2032 2033 2034 Opportunistic and prudent refinancing Maintain ample liquidity Excess cash + revolver capacity (currently undrawn) Maintain flexibility via prepayable / callable debt Continually optimize blended borrowing cost across all debt Debt maturities aligned with cash generation timing and strong liquidity provide structural safeguard to the balance sheet Debt Maturity Profile Pre1 and Post Refinancing 9 Consistent execution against deleveraging plans → Refinancing transaction completed in Dec 2025, further fortifying maturity profile → Fully paid off $130 M remaining balance on five-year term loam → Closed Micromax divestiture, net proceeds planned to be utilized for debt paydown → Strong liquidity position with $1.3 B in cash and cash equivalents at quarter-end and $1.75 B undrawn revolving credit facility → Self-help actions to increase earnings and free cash flow\* drive incremental benefit in 2026 and beyond 1 As of December 1, 2025 Debt Management Principles $2.1billion 2026 + 2027 DEBT MATURITIES2 35% % of NOTES WITH CALL FEATURE2 PRE-REFINANCE1 POST-REFINANCE Post refinance, 2026 - 2028 average debt maturity reduced to $1.1 B, aligning with conservative estimates of cash generation 5.31% EFFECTIVE NET BORROWING RATE2 2Calculations are based on (1) initial debt balances as of September 30, 2025, adjusted to include $200 million repaid after September 30, 2025 under the Company's five-year term loan credit agreement due 2027, (2) the inclusion of annualized coupon step-ups based on current credit ratings, (3) the inclusion of the impact of all cross-currency swaps, (4) 4.14% SOFR, (5) a EUR/USD exchange rate of 1.1741 as of September 30, 2025, and (6) the exclusion of non-cash interest expenses

------

![](q420258-kex991b010.jpg)

Strong and sustainable free cash flow\* generation and divestitures drive deleveraging Free Cash Flow\* and Divestitures ($M) 10 Sustainable cash generation capabilities accelerate debt paydown Accelerating cash flow capabilities and strategic divestitures… \* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures. Net Debt ($B) … increasingly deployed to deleveraging ~$2.6 B Cash Generation 2023 - 2025 ~ $500 ~$2.5 B+ of Baseline Cash Generation 2026 – 2027 Targets Achieved ~$2.0 B Reduction Net of currency impact Net of $0.6 B in dividends 2026 Targeting FCF at $650M - $750M 2 27 Targeting growth in baseline FCF from additional cost & commercial actions and lower restructuring costs 1 2 3 0 500 1000 1500 2023 2024 2025 2026 2027 Divestitures Transaction Price $500 ~$500 ~$500 MicromaxFood Ingredients Progress towards $1.0 B divestiture objective 1000 1500 2023 2024 2025 2026 2027 $1,320 $498 $773 Free Cash Flow 12/31/2022 12/31/2025 12/31/2027 $13.2 $11.3 Targeted < $9 Expecting ~$2.5 B Reduction Targeting virtually all cash proceeds deployed to deleveraging ~ ~$700

------

![](q420258-kex991b011.jpg)

Actions driving EM earnings in low demand environment while reinforcing foundation for future growth 11 ✓ Lower cost structure provides significant earnings leverage in demand recovery ✓ Revitalization of pipeline leverages broad portfolio and application development capabilities ✓ Execution of strategic actions positions EM for long-term success \* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures. ACTUAL ESTIMATE $143 $124 $213 $200 $183 $220 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 COST REDUCTION ACTIONS STRUCTURAL INVENTORY REDUCTION TOPLINE & MARGIN GROWTH IMPROVED PIPELINE QUALITY Strong focus and execution of actions in EM … ... driving resilient performance in a low demand environment ✓ SG&A reduction ✓ Distribution network improvements ✓ Global asset footprint optimization ✓ FY 2025 inventory reduction of $100M+ ✓ Multi-year journey towards optimization ✓ Strategic marketing implementation ✓ Value based pricing ✓ Mix improvement ✓ Focus on high margin and high growth programs ✓ Pipeline quality ✓ 'Value' over 'volume' EM ADJUSTED EBIT\*, $MM ~

------

![](q420258-kex991b012.jpg)

Strong focus on actions to offset headwinds and drive AC earnings 12 \* Represents a non-GAAP measure. For information on historical non-GAAP financial measures used by the Company, including definitions and reconciliations to comparable GAAP financial measures, please refer to the Non-US GAAP Financial Measures and Supplemental Information document available on our website, investors.celanese.com, under Financial Information/Non-GAAP Financial Measures. STRATEGIC INITIATIVES DAILY OPERATING MODEL Strong focus and execution of actions in AC ...strengthen business foundation and expand operating leverage for future earnings growth ...enables agile responses to market conditions, maximizing earnings performance ✓ BLOCK OPERATION OF SINGAPORE/FRA UNIT ✓ INTENDED LANAKEN SITE CLOSURE ✓ MANUFACTURING DIGITALIZATION ✓ RAW MATERIAL PRODUCTIVITY ✓ TARGETED PRICE INCREASES ✓ COMMERCIALIZING SUSTAINABILITY OFFERINGS 1. Challenges in Acetate Tow 2. Weak Western Hemisphere Demand 3. Asia margins impacted by China supply Key impacts to AC earnings AT was the largest headwind to AC earnings in 2025, actions to address are already in play ✓ DOWNSTREAM GROWTH ✓ STRATEGIC CONTRACTS productivity and flexibility in reacting to market dynamics short-term market dislocations & long-term value-based pricing providing strong foundation and ratable earnings qualify grades to meet evolving customer application needs efficiency, productivity and future-proofing flexing global network to optimize cost profile partnering with customers to drive ECO-CC sales lower risks and drive productivity ✓ MAXIMIZE CASH FLOW VELOCITY global working capital and inventory execution

------

![](q420258-kex991b013.jpg)

$25 $15 $30 - $50 $20 - $30 $10 - $20 $80 $10 Achieved over $120 M cost savings in 2025; targeting incremental opportunities of ~$50 M - $70 M in 2026 13 Near Term Cost Reductions Engineered Materials Complexity Reduction Acetyl Chain Productivity $90 million of targeted annualized savings primarily through headcount reductions actioned in 2025 $50 million of plant and distribution productivity $50 - $100 million of targeted annualized savings primarily through distribution network improvements, footprint actions, and SG&A Cost Reduction Initiatives Cost Reduction Realization Targets by Year ($M) 2026 Expected In-Year Realization: ~$50-$70 M Cost reductions are helping to set a firm foundation for long-term growth ~$15 + 2025 2026 2027 2026 2027 Lanaken ~$5-$10M ~$15-$20M Productivity projects ~$5-$10M TBD

------

![](q420258-kex991b014.jpg)

Celanese Offers a Compelling Investment Opportunity Our mission is to position Celanese as a top quartile company for total shareholder return by delivering earnings growth in any environment 14 Leadership driving change Actions underway to deliver near-term earnings improvement Strong earnings leverage as demand recovers Laser focused on deleveraging History of innovation as customer solutions provider Attractive valuation with upside potential for stock

------

## Exhibit 99.2

![celogoa.jpg](celogoa.jpg)

**Exhibit 99.2**

**<u>Non-U.S. GAAP Financial Measures and Supplemental Information</u>**

**February 17, 2026**

*In this document, the terms the "Company," "we" and "our" refer to Celanese Corporation and its subsidiaries on a consolidated basis.*

***Purpose***

*The purpose of this document is to provide information of interest to investors, analysts and other parties including supplemental financial information and reconciliations and other information concerning our use of non-U.S. GAAP financial measures. This document is updated quarterly.*

***Presentation***

*This document presents the Company's two business segments, Engineered Materials and the Acetyl Chain.*

***Use of Non-U.S. GAAP Financial Measures***

*From time to time, management may publicly disclose certain numerical "non-GAAP financial measures" in the course of our earnings releases, financial presentations, earnings conference calls, investor and analyst meetings and otherwise. For these purposes, the Securities and Exchange Commission ("SEC") defines a "non-GAAP financial measure" as a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that effectively exclude amounts, included in the most directly comparable measure calculated and presented in accordance with U.S. GAAP, and vice versa for measures that include amounts, or are subject to adjustments that effectively include amounts, that are excluded from the most directly comparable U.S. GAAP measure so calculated and presented. For these purposes, "GAAP" refers to generally accepted accounting principles in the United States.*

*Non-GAAP financial measures disclosed by management are provided as additional information to investors, analysts and other parties because the Company believes them to be important supplemental measures for assessing our financial and operating results and as a means to evaluate our financial condition and period-to-period comparisons. These non-GAAP financial measures should be viewed as supplemental to, and should not be considered in isolation or as alternatives to, net earnings (loss), operating profit (loss), operating margin, cash flow from operating activities (together with cash flow from investing and financing activities), earnings per share or any other U.S. GAAP financial measure. These non-GAAP financial measures should be considered within the context of our complete audited and unaudited financial results for the given period, which are available on the Financial Information/Financial Document Library page of our website, investors.celanese.com. The definition and method of calculation of the non-GAAP financial measures used herein may be different from other companies' methods for calculating measures with the same or similar titles. Investors, analysts and other parties should understand how another company calculates such non-GAAP financial measures before comparing the other company's non-GAAP financial measures to any of our own. These non-GAAP financial measures may not be indicative of the historical operating results of the Company nor are they intended to be predictive or projections of future results.*

*Pursuant to the requirements of SEC Regulation G, whenever we refer to a non-GAAP financial measure, we will also present in this document, in the presentation itself or on a Form 8-K in connection with the presentation on the Financial Information/Financial Document Library page of our website, investors.celanese.com, to the extent practicable, the most directly comparable financial measure calculated and presented in accordance with GAAP, along with a reconciliation of the differences between the non-GAAP financial measure we reference and such comparable GAAP financial measure.*

*This document includes definitions and reconciliations of non-GAAP financial measures used from time to time by the Company.*

***Specific Measures Used***

*This document provides information about the following non-GAAP measures: adjusted EBIT, adjusted EBIT margin, operating EBITDA, operating EBITDA margin, operating profit (loss) attributable to Celanese Corporation, adjusted earnings per share, net debt, free cash flow and return on invested capital (adjusted). The most directly comparable financial measure presented in accordance with U.S. GAAP in our consolidated financial statements for adjusted EBIT and operating EBITDA is net earnings (loss) attributable to Celanese Corporation; for adjusted EBIT margin and operating EBITDA margin is operating margin; for operating profit (loss) attributable to Celanese Corporation is operating profit (loss); for adjusted earnings per share is earnings (loss) from continuing operations attributable to Celanese Corporation per common share-diluted; for net debt* 

------

![celogoa.jpg](celogoa.jpg)

*is total debt; for free cash flow is net cash provided by (used in) operations; and for return on invested capital (adjusted) is net earnings (loss) attributable to Celanese Corporation divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity.*

*Definitions*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Adjusted EBIT is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense and taxes, and further adjusted for Certain Items (refer to <u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>). We believe that adjusted EBIT provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of unusual, non-operational or restructuring-related activities that affect comparability. Our management recognizes that adjusted EBIT has inherent limitations because of the excluded items. Adjusted EBIT is one of the measures management uses for planning and budgeting, monitoring and evaluating financial and operating results and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted EBIT on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Adjusted EBIT margin is defined by the Company as adjusted EBIT divided by net sales. Adjusted EBIT margin has the same uses and limitations as adjusted EBIT.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Operating EBITDA is a performance measure used by the Company and is defined by the Company as net earnings (loss) attributable to Celanese Corporation, plus (earnings) loss from discontinued operations, less interest income, plus interest expense, plus refinancing expense, taxes and depreciation and amortization, and further adjusted for Certain Items, which Certain Items include accelerated depreciation and amortization expense. Operating EBITDA is equal to adjusted EBIT plus depreciation and amortization. We believe that operating EBITDA provides transparent and useful information to investors, analysts and other parties in evaluating our operating performance relative to our peer companies. We do not provide reconciliations for operating EBITDA on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Operating EBITDA margin is defined by the Company as operating EBITDA divided by net sales. Operating EBITDA margin has the same uses and limitations as operating EBITDA.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Operating profit (loss) attributable to Celanese Corporation is defined by the Company as operating profit (loss), less earnings (loss) attributable to noncontrolling interests ("NCI"). We believe that operating profit (loss) attributable to Celanese Corporation provides transparent and useful information to management, investors, analysts and other parties in evaluating our core operational performance. Operating margin attributable to Celanese Corporation is defined by the Company as operating profit (loss) attributable to Celanese Corporation divided by net sales. Operating margin attributable to Celanese Corporation has the same uses and limitations as operating profit (loss) attributable to Celanese Corporation.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Adjusted earnings per share is a performance measure used by the Company and is defined by the Company as earnings (loss) from continuing operations attributable to Celanese Corporation, adjusted for income tax (provision) benefit, Certain Items, and refinancing and related expenses, divided by the number of basic common shares and dilutive restricted stock units and stock options calculated using the treasury method. We believe that adjusted earnings per share provides transparent and useful information to management, investors, analysts and other parties in evaluating and assessing our primary operating results from period-to-period after removing the impact of the above stated items that affect comparability and as a performance metric in the Company's incentive compensation plan. We do not provide reconciliations for adjusted earnings per share on a forward-looking basis (including those contained in this document) when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of Certain Items, such as mark-to-market pension gains and losses, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.*

*Note: The income tax expense (benefit) on Certain Items ("Non-GAAP adjustments") is determined using the applicable rates in the taxing jurisdictions in which the Non-GAAP adjustments occurred and includes both current and deferred income tax expense (benefit). The income tax rate used for adjusted earnings per share approximates the midpoint in a range of forecasted tax rates for the year. This range may include certain partial or full-year forecasted tax opportunities and related costs, where applicable, and specifically excludes changes in uncertain tax positions, discrete recognition of GAAP items on a quarterly basis, other pre-tax items adjusted out of our GAAP earnings for adjusted earnings per share purposes and changes in management's assessments regarding the ability to realize deferred tax assets for GAAP. In determining the adjusted earnings per share tax rate, we reflect the impact of foreign tax credits when utilized, or expected to be utilized, absent discrete events impacting the timing of foreign tax credit utilization. We analyze this rate quarterly and adjust it if there is a material change in the range of forecasted tax rates; an updated forecast would not necessarily result in a change to our tax rate used for adjusted earnings per share. The adjusted tax rate is an estimate and may differ from the actual tax rate used for GAAP reporting in any given reporting period. <u>[Table 3a](#i314c3b6c9ca9490fbb2137b9416a9e51_22)</u> summarizes the reconciliation of our estimated GAAP effective tax rate to the adjusted tax* 

------

![celogoa.jpg](celogoa.jpg)

*rate. The estimated GAAP rate excludes discrete recognition of GAAP items due to our inability to forecast such items. As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate to the adjusted tax rate for actual results.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operations, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures. We believe that free cash flow provides useful information to management, investors, analysts and other parties in evaluating the Company's liquidity and credit quality assessment because it provides an indication of the long-term cash generating ability of our business. Although we use free cash flow as a measure to assess the liquidity generated by our business, the use of free cash flow has important limitations, including that free cash flow does not reflect the cash requirements necessary to service our indebtedness, lease obligations, unconditional purchase obligations or pension and postretirement funding obligations. Free cash flow is not a measure of cash available for discretionary expenditures since the Company has certain debt service and finance lease payments that are not deducted from that measure. We do not provide reconciliations for free cash flow on a forward-looking basis when we are unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amount of items such as working capital changes, fluctuations in foreign currency exchange rates, the impact and timing of potential acquisitions and divestitures, and other structural changes, that have not yet occurred, are out of our control and/or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Net debt is defined by the Company as total debt less cash and cash equivalents. We believe that net debt provides useful information to management, investors, analysts and other parties in evaluating changes to the Company's capital structure and credit quality assessment.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Return on invested capital (adjusted) is defined by the Company as adjusted EBIT, tax effected using the adjusted tax rate, divided by the sum of the average of beginning and end of the year short- and long-term debt and Celanese Corporation shareholders' equity. We believe that return on invested capital (adjusted) provides useful information to management, investors, analysts and other parties in order to assess our income generation from the point of view of our shareholders and creditors who provide us with capital in the form of equity and debt and whether capital invested in the Company yields competitive returns.*

***Supplemental Information***

*Supplemental Information we believe to be of interest to investors, analysts and other parties includes the following:*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Net sales for each of our business segments and the percentage increase or decrease in net sales attributable to price, volume, currency and other factors for each of our business segments.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Cash dividends received from our equity investments.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• For those consolidated ventures in which the Company owns or is exposed to less than 100% of the economics, the outside shareholders' interests are shown as NCI. Amounts referred to as "attributable to Celanese Corporation" are net of any applicable NCI.*

***Results Unaudited***

*The results in this document, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.* 

*Certain prior period amounts have been revised to correct for certain prior period immaterial errors. See Note 1 to our Annual Report on Form 10-K for the annual period ending December 31, 2025.*

------

![celogoa.jpg](celogoa.jpg)

**Table 1**

**Adjusted EBIT and Operating EBITDA - Reconciliation of Non-GAAP Measures - Unaudited**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | **Q3 '25** | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | **Q3 '24** | **Q2 '24** | **Q1 '24** |
| | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** |
| Net earnings (loss) attributable to Celanese Corporation | (1165) | 19 | (1357) | 197 | (24) | (1542) | (1925) | 113 | 152 | 118 |
| (Earnings) loss from discontinued operations | 21 | 6 |  | 10 | 5 | 8 | 5 | 2 | 1 |  |
| Interest income | (24) | (6) | (7) | (7) | (4) | (33) | (5) | (5) | (10) | (13) |
| Interest expense | 701 | 177 | 177 | 177 | 170 | 676 | 164 | 169 | 174 | 169 |
| Refinancing expense | 68 | 36 |  |  | 32 |  |  |  |  |  |
| Income tax provision (benefit) | (90) | (15) | (7) | (77) | 9 | 507 | 384 | 61 | 29 | 33 |
| Certain Items attributable to Celanese Corporation (<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>) | 1639 | 34 | 1520 | 42 | 43 | 2009 | 1696 | 114 | 102 | 97 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Adjusted EBIT** | 1150 | 251 | 326 | 342 | 231 | 1625 | 319 | 454 | 448 | 404 |
| Depreciation and amortization expense<sup>(1)</sup> | 743 | 184 | 191 | 188 | 180 | 728 | 184 | 187 | 181 | 176 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Operating EBITDA** | 1893 | 435 | 517 | 530 | 411 | 2353 | 503 | 641 | 629 | 580 |

---

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | **Q3 '25** | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | **Q3 '24** | **Q2 '24** | **Q1 '24** |
| | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** |
| Engineered Materials | 6 | 1 | 3 | 2 |  | 73 | 1 | 16 | 11 | 45 |
| Acetyl Chain | 11 | 11 |  |  |  |  |  |  |  |  |
| Other Activities<sup>(2)</sup> |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Accelerated depreciation and amortization expense** | 17 | 12 | 3 | 2 |  | 73 | 1 | 16 | 11 | 45 |
| Depreciation and amortization expense<sup>(1)</sup> | 743 | 184 | 191 | 188 | 180 | 728 | 184 | 187 | 181 | 176 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total depreciation and amortization expense** | 760 | 196 | 194 | 190 | 180 | 801 | 185 | 203 | 192 | 221 |

---

______________________________

<sup>(1)</sup> Excludes accelerated depreciation and amortization expense as detailed in the table above, which amounts are included in Certain Items above.

<sup>(2)</sup> Other Activities includes corporate Selling, general and administrative ("SG&A") expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

------

![celogoa.jpg](celogoa.jpg)

**Table 2**

**Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited**

---

| | | | | | | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **Q4 '25** | **Q4 '25** | **Q3 '25** | **Q3 '25** | **Q2 '25** | **Q2 '25** | **Q1 '25** | **Q1 '25** | **2024** | **2024** | **Q4 '24** | **Q4 '24** | **Q3 '24** | **Q3 '24** | **Q2 '24** | **Q2 '24** | **Q1 '24** | **Q1 '24** |
| | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** |
| **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** | **Operating Profit (Loss) / Operating Margin** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | (958) | (17.8)% | 111 | 8.7% | (1327) | (95.9)% | 164 | 11.4% | 94 | 7.3% | (1197) | (21.4)% | (1521) | (119.9)% | 100 | 6.8% | 136 | 9.3% | 88 | 6.4% |
| &nbsp;&nbsp;&nbsp;Acetyl Chain | 539 | 12.7% | 90 | 9.6% | 135 | 12.7% | 153 | 13.7% | 161 | 14.4% | 946 | 19.9% | 215 | 19.4% | 238 | 20.0% | 241 | 20.0% | 252 | 20.0% |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(1)</sup> | (367) |  | (108) |  | (83) |  | (86) |  | (90) |  | (469) |  | (113) |  | (93) |  | (130) |  | (133) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | (786) | (8.2)% | 93 | 4.2% | (1275) | (52.7)% | 231 | 9.1% | 165 | 6.9% | (720) | (7.0)% | (1419) | (60.2)% | 245 | 9.3% | 247 | 9.3% | 207 | 7.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Net Earnings (Loss) Attributable to NCI for Engineered Materials | 6 |  |  |  | 3 |  | 1 |  | 2 |  | (1) |  | 2 |  | 2 |  | (4) |  | (1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Net Earnings (Loss) Attributable to NCI for Acetyl Chain | 8 |  | 3 |  | 1 |  | 2 |  | 2 |  | 9 |  | 1 |  | 2 |  | 2 |  | 4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating Profit (Loss) Attributable to Celanese Corporation | (800) | (8.4)% | 90 | 4.1% | (1279) | (52.9)% | 228 | 9.0% | 161 | 6.7% | (728) | (7.1)% | (1422) | (60.3)% | 241 | 9.1% | 249 | 9.4% | 204 | 7.8% |
| **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** | **Operating Profit (Loss) / Operating Margin Attributable to Celanese Corporation** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | (964) | (17.9)% | 111 | 8.7% | (1330) | (96.1)% | 163 | 11.3% | 92 | 7.1% | (1196) | (21.4)% | (1523) | (120.0)% | 98 | 6.6% | 140 | 9.5% | 89 | 6.5% |
| &nbsp;&nbsp;&nbsp;Acetyl Chain | 531 | 12.5% | 87 | 9.3% | 134 | 12.6% | 151 | 13.5% | 159 | 14.2% | 937 | 19.7% | 214 | 19.3% | 236 | 19.8% | 239 | 19.9% | 248 | 19.7% |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(1)</sup> | (367) |  | (108) |  | (83) |  | (86) |  | (90) |  | (469) |  | (113) |  | (93) |  | (130) |  | (133) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | (800) | (8.4)% | 90 | 4.1% | (1279) | (52.9)% | 228 | 9.0% | 161 | 6.7% | (728) | (7.1)% | (1422) | (60.3)% | 241 | 9.1% | 249 | 9.4% | 204 | 7.8% |
| **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** | **Equity Earnings and Dividend Income, Other Income (Expense) Attributable to Celanese Corporation** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | 109 |  | 32 |  | 35 |  | 25 |  | 17 |  | 178 |  | 33 |  | 46 |  | 49 |  | 50 |  |
| &nbsp;&nbsp;&nbsp;Acetyl Chain | 132 |  | 42 |  | 44 |  | 43 |  | 3 |  | 138 |  | 35 |  | 34 |  | 33 |  | 36 |  |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(1)</sup> | 15 |  | 3 |  | 4 |  | 3 |  | 5 |  | 48 |  | 4 |  | 16 |  | 13 |  | 15 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | 256 |  | 77 |  | 83 |  | 71 |  | 25 |  | 364 |  | 72 |  | 96 |  | 95 |  | 101 |  |
| **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** | **Non-Operating Pension and Other Post-Retirement Employee Benefit (Expense) Income Attributable to Celanese Corporation** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | 3 |  | 3 |  |  |  |  |  |  |  | 8 |  | 8 |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Acetyl Chain |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(1)</sup> | 52 |  | 47 |  | 2 |  | 1 |  | 2 |  | (28) |  | (35) |  | 3 |  | 2 |  | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | 55 |  | 50 |  | 2 |  | 1 |  | 2 |  | (20) |  | (27) |  | 3 |  | 2 |  | 2 |  |
| **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** | **Certain Items Attributable to Celanese Corporation** **(**<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>**)** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | 1572 |  | 37 |  | 1495 |  | 25 |  | 15 |  | 1851 |  | 1625 |  | 91 |  | 74 |  | 61 |  |
| &nbsp;&nbsp;&nbsp;Acetyl Chain | 32 |  | 17 |  | 9 |  | 1 |  | 5 |  | 22 |  | 3 |  | 5 |  | 4 |  | 10 |  |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(1)</sup> | 35 |  | (20) |  | 16 |  | 16 |  | 23 |  | 136 |  | 68 |  | 18 |  | 24 |  | 26 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | 1639 |  | 34 |  | 1520 |  | 42 |  | 43 |  | 2009 |  | 1696 |  | 114 |  | 102 |  | 97 |  |
| **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** | **Adjusted EBIT / Adjusted EBIT Margin** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | 720 | 13.4% | 183 | 14.3% | 200 | 14.5% | 213 | 14.8% | 124 | 9.6% | 841 | 15.0% | 143 | 11.3% | 235 | 15.9% | 263 | 17.9% | 200 | 14.5% |
| &nbsp;&nbsp;&nbsp;Acetyl Chain | 695 | 16.4% | 146 | 15.5% | 187 | 17.6% | 195 | 17.5% | 167 | 15.0% | 1097 | 23.0% | 252 | 22.7% | 275 | 23.1% | 276 | 23.0% | 294 | 23.3% |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(1)</sup>  | (265) |  | (78) |  | (61) |  | (66) |  | (60) |  | (313) |  | (76) |  | (56) |  | (91) |  | (90) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | 1150 | 12.0% | 251 | 11.4% | 326 | 13.5% | 342 | 13.5% | 231 | 9.7% | 1625 | 15.8% | 319 | 13.5% | 454 | 17.1% | 448 | 16.9% | 404 | 15.5% |

---

___________________________

<sup>(1)</sup> Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

------

![celogoa.jpg](celogoa.jpg)

**Table 2**

**Supplemental Segment Data and Reconciliation of Segment Adjusted EBIT and Operating EBITDA - Non-GAAP Measures - Unaudited (cont.)**

---

| | | | | | | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **Q4 '25** | **Q4 '25** | **Q3 '25** | **Q3 '25** | **Q2 '25** | **Q2 '25** | **Q1 '25** | **Q1 '25** | **2024** | **2024** | **Q4 '24** | **Q4 '24** | **Q3 '24** | **Q3 '24** | **Q2 '24** | **Q2 '24** | **Q1 '24** | **Q1 '24** |
| | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** |
| **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> | **Depreciation and Amortization Expense**<sup>(1)</sup> |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | 441 |  | 105 |  | 115 |  | 112 |  | 109 |  | 437 |  | 114 |  | 111 |  | 110 |  | 102 |  |
| &nbsp;&nbsp;&nbsp;Acetyl Chain | 252 |  | 64 |  | 63 |  | 64 |  | 61 |  | 244 |  | 63 |  | 63 |  | 61 |  | 57 |  |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(2)</sup>  | 50 |  | 15 |  | 13 |  | 12 |  | 10 |  | 47 |  | 7 |  | 13 |  | 10 |  | 17 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | 743 |  | 184 |  | 191 |  | 188 |  | 180 |  | 728 |  | 184 |  | 187 |  | 181 |  | 176 |  |
| **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** | **Operating EBITDA / Operating EBITDA Margin** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Engineered Materials | 1161 | 21.5% | 288 | 22.6% | 315 | 22.8% | 325 | 22.5% | 233 | 18.1% | 1278 | 22.8% | 257 | 20.3% | 346 | 23.4% | 373 | 25.4% | 302 | 21.9% |
| &nbsp;&nbsp;&nbsp;Acetyl Chain | 947 | 22.4% | 210 | 22.3% | 250 | 23.6% | 259 | 23.2% | 228 | 20.4% | 1341 | 28.2% | 315 | 28.4% | 338 | 28.4% | 337 | 28.0% | 351 | 27.8% |
| &nbsp;&nbsp;&nbsp;Other Activities<sup>(2)</sup> | (215) |  | (63) |  | (48) |  | (54) |  | (50) |  | (266) |  | (69) |  | (43) |  | (81) |  | (73) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total** | 1893 | 19.8% | 435 | 19.7% | 517 | 21.4% | 530 | 20.9% | 411 | 17.2% | 2353 | 22.9% | 503 | 21.3% | 641 | 24.2% | 629 | 23.7% | 580 | 22.2% |

---

___________________________

<sup>(1)</sup> Excludes accelerated depreciation and amortization expense, which amounts are included in Certain Items above. See <u>[Table 1](#i314c3b6c9ca9490fbb2137b9416a9e51_7)</u> for details.

<sup>(2)</sup> Other Activities includes corporate SG&A expenses, results of captive insurance companies and certain components of net periodic benefit cost (interest cost, expected return on plan assets and net actuarial gains and losses).

------

![celogoa.jpg](celogoa.jpg)

**Table 3**

**Adjusted Earnings (Loss) per Share - Reconciliation of a Non-GAAP Measure - Unaudited**

---

| | | | | | | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **Q4 '25** | **Q4 '25** | **Q3 '25** | **Q3 '25** | **Q2 '25** | **Q2 '25** | **Q1 '25** | **Q1 '25** | **2024** | **2024** | **Q4 '24** | **Q4 '24** | **Q3 '24** | **Q3 '24** | **Q2 '24** | **Q2 '24** | **Q1 '24** | **Q1 '24** |
| | | **per share** | | **per share** | | **per share** | | **per share** | | **per share** | | **per share** | | **per share** | | **per share** | | **per share** | | **per share** |
| | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** | **(In $ millions, except per share data)** |
| Earnings (loss) from continuing operations attributable to Celanese Corporation | (1144) | (10.44) | 25 | 0.23 | (1357) | (12.39) | 207 | 1.89 | (19) | (0.17) | (1534) | (14.04) | (1920) | (17.55) | 115 | 1.05 | 153 | 1.40 | 118 | 1.08 |
| Income tax provision (benefit) | (90) |  | (15) |  | (7) |  | (77) |  | 9 |  | 507 |  | 384 |  | 61 |  | 29 |  | 33 |  |
| &nbsp;&nbsp;Earnings (loss) from continuing operations before tax | (1234) |  | 10 |  | (1364) |  | 130 |  | (10) |  | (1027) |  | (1536) |  | 176 |  | 182 |  | 151 |  |
| Certain Items attributable to Celanese Corporation (<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>) | 1639 |  | 34 |  | 1520 |  | 42 |  | 43 |  | 2009 |  | 1696 |  | 114 |  | 102 |  | 97 |  |
| Refinancing and related expenses | 68 |  | 36 |  |  |  |  |  | 32 |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Adjusted earnings (loss) from continuing operations before tax | 473 |  | 80 |  | 156 |  | 172 |  | 65 |  | 982 |  | 160 |  | 290 |  | 284 |  | 248 |  |
| Income tax (provision) benefit on adjusted earnings<sup>(1)</sup> | (36) |  | (6) |  | (9) |  | (15) |  | (6) |  | (88) |  | (14) |  | (26) |  | (26) |  | (22) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Adjusted earnings (loss) from continuing operations**<sup>(2)</sup> | 437 | 3.98 | 74 | 0.67 | 147 | 1.34 | 157 | 1.43 | 59 | 0.54 | 894 | 8.18 | 146 | 1.33 | 264 | 2.41 | 258 | 2.36 | 226 | 2.06 |
|  | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> | **Diluted shares (in millions)**<sup>(3)</sup> |
| Weighted average shares outstanding | 109.5 |  | 109.6 |  | 109.6 |  | 109.5 |  | 109.4 |  | 109.3 |  | 109.4 |  | 109.3 |  | 109.3 |  | 109.1 |  |
| Incremental shares attributable to equity awards | 0.2 |  | 0.2 |  |  |  | 0.2 |  |  |  |  |  |  |  | 0.2 |  | 0.2 |  | 0.4 |  |
| &nbsp;&nbsp;Total diluted shares | 109.7 |  | 109.8 |  | 109.6 |  | 109.7 |  | 109.4 |  | 109.3 |  | 109.4 |  | 109.5 |  | 109.5 |  | 109.5 |  |

---

______________________________

<sup>(1)</sup> Calculated using adjusted effective tax rates (<u>[Table 3a](#i314c3b6c9ca9490fbb2137b9416a9e51_22)</u>) as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | **Q3 '25** | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | **Q3 '24** | **Q2 '24** | **Q1 '24** |
| Adjusted effective tax rate | 8 | 8 | 6 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |

---

<sup>(2)</sup> Excludes the immediate recognition of actuarial gains and losses and the impact of actual vs. expected plan asset returns.

---

| | | |
|:---|:---|:---|
| | **Actual Plan Asset Returns** | **Expected Plan Asset Returns** |
| | **(In percentages)** | **(In percentages)** |
| Q4 '25 & 2025 | 7.8 | 5.3 |
| Q4 '24 & 2024 | 2.5 | 5.3 |

---

<sup>(3)</sup> Potentially dilutive shares are included in the adjusted earnings per share calculation when adjusted earnings are positive.

------

![celogoa.jpg](celogoa.jpg)

**Table 3a**

**Adjusted Tax Rate - Reconciliation of a Non-GAAP Measure - Unaudited**

---

| | | |
|:---|:---|:---|
| | **Actual** | **Actual** |
| | **2025** | **2024** |
| | **(In percentages)** | **(In percentages)** |
| U.S. GAAP annual effective tax rate | 7 | (50) |
| Discrete quarterly recognition of GAAP items<sup>(1)</sup> | 17 | 1 |
| Tax impact of other charges and adjustments<sup>(2)</sup> | (12) | 98 |
| Changes in valuation allowances, excluding impact of other charges and adjustments<sup>(3)</sup> | (12) | (40) |
| Other, includes effect of discrete current year transactions<sup>(4)</sup> | 8 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Adjusted tax rate** | 8 | 9 |

---

______________________________

*Note: As part of the year-end reconciliation, we will update the reconciliation of the GAAP effective tax rate for actual results.*

<sup>(1)</sup> Such as changes in tax laws (including U.S. tax reform), deferred taxes on outside basis differences, changes in uncertain tax positions and prior year audit adjustments.

<sup>(2)</sup> Reflects the tax impact on pre-tax adjustments presented in Certain Items (<u>[Table 8](#i314c3b6c9ca9490fbb2137b9416a9e51_43)</u>), which are excluded from pre-tax income for adjusted earnings per share purposes.

<sup>(3)</sup> Reflects changes in valuation allowances related to changes in judgment regarding the realizability of deferred tax assets or current year operations, excluding other charges and adjustments.

<sup>(4)</sup> Includes tax impacts related to full-year actual tax opportunities and related costs, as well as current year realization of U.S. GAAP benefits deferred in prior years.

------

![celogoa.jpg](celogoa.jpg)

**Table 4**

**Net Sales by Segment - Unaudited**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | **Q3 '25** | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | **Q3 '24** | **Q2 '24** | **Q1 '24** |
| | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** |
| Engineered Materials | 5390 | 1277 | 1384 | 1442 | 1287 | 5595 | 1269 | 1481 | 1467 | 1378 |
| Acetyl Chain | 4232 | 940 | 1061 | 1115 | 1116 | 4763 | 1110 | 1190 | 1202 | 1261 |
| Intersegment eliminations<sup>(1)</sup> | (78) | (13) | (26) | (25) | (14) | (90) | (21) | (23) | (18) | (28) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net sales** | 9544 | 2204 | 2419 | 2532 | 2389 | 10268 | 2358 | 2648 | 2651 | 2611 |

---

___________________________

<sup>(1)</sup> Includes intersegment sales primarily related to the Acetyl Chain.

------

![celogoa.jpg](celogoa.jpg)

**Table 4a**

**Factors Affecting Segment Net Sales Sequentially - Unaudited**

**Three Months Ended December 31, 2025 Compared to Three Months Ended September 30, 2025** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (6) | (2) |  | (8) |
| Acetyl Chain | (10) | (1) |  | (11) |
| **Total Company** | (7) | (2) |  | (9) |

---

**Three Months Ended September 30, 2025 Compared to Three Months Ended June 30, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (6) | 1 | 1 | (4) |
| Acetyl Chain | (2) | (4) | 1 | (5) |
| **Total Company** | (4) | (1) | 1 | (4) |

---

**Three Months Ended June 30, 2025 Compared to Three Months Ended March 31, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | 9 |  | 3 | 12 |
| Acetyl Chain | (1) | (2) | 3 |  |
| **Total Company** | 4 | (1) | 3 | 6 |

---

**Three Months Ended March 31, 2025 Compared to Three Months Ended December 31, 2024** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials |  | 2 | (1) | 1 |
| Acetyl Chain | 3 | (1) | (1) | 1 |
| **Total Company** | 2 |  | (1) | 1 |

---

**Three Months Ended December 31, 2024 Compared to Three Months Ended September 30, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (10) | (3) | (1) | (14) |
| Acetyl Chain | (4) | (2) | (1) | (7) |
| **Total Company** | (7) | (3) | (1) | (11) |

---

**Three Months Ended September 30, 2024 Compared to Three Months Ended June 30, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials |  |  | 1 | 1 |
| Acetyl Chain |  | (2) | 1 | (1) |
| **Total Company** |  | (1) | 1 |  |

---

**Three Months Ended June 30, 2024 Compared to Three Months Ended March 31, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | 7 |  | (1) | 6 |
| Acetyl Chain | (1) | (4) |  | (5) |
| **Total Company** | 4 | (2) |  | 2 |

---

**Three Months Ended March 31, 2024 Compared to Three Months Ended December 31, 2023**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (1) |  |  | (1) |
| Acetyl Chain | 5 | 1 | 1 | 7 |
| **Total Company** | 1 | 1 |  | 2 |

---

------

![celogoa.jpg](celogoa.jpg)

**Table 4b**

**Factors Affecting Segment Net Sales Year Over Year - Unaudited**

**Three Months Ended December 31, 2025 Compared to Three Months Ended December 31, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (2) |  | 3 | 1 |
| Acetyl Chain | (10) | (7) | 2 | (15) |
| **Total Company** | (6) | (3) | 2 | (7) |

---

**Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (8) | (1) | 2 | (7) |
| Acetyl Chain | (4) | (8) | 1 | (11) |
| **Total Company** | (6) | (4) | 1 | (9) |

---

**Three Months Ended June 30, 2025 Compared to Three Months Ended June 30, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (3) | (1) | 2 | (2) |
| Acetyl Chain | (2) | (7) | 2 | (7) |
| **Total Company** | (2) | (4) | 2 | (4) |

---

**Three Months Ended March 31, 2025 Compared to Three Months Ended March 31, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (4) | (2) | (1) | (7) |
| Acetyl Chain | (6) | (4) | (1) | (11) |
| **Total Company** | (5) | (3) | (1) | (9) |

---

**Three Months Ended December 31, 2024 Compared to Three Months Ended December 31, 2023**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (6) | (3) |  | (9) |
| Acetyl Chain | (2) | (4) |  | (6) |
| **Total Company** | (4) | (4) |  | (8) |

---

**Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (1) | (2) |  | (3) |
| Acetyl Chain | 1 | (3) |  | (2) |
| **Total Company** |  | (3) |  | (3) |

---

**Three Months Ended June 30, 2024 Compared to Three Months Ended June 30, 2023**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (2) | (4) | (1) | (7) |
| Acetyl Chain | 4 | (6) | (1) | (3) |
| **Total Company** | 1 | (5) | (1) | (5) |

---

**Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (12) | (2) | (1) | (15) |
| Acetyl Chain | 11 | (10) |  | 1 |
| **Total Company** | (2) | (5) | (1) | (8) |

---

------

![celogoa.jpg](celogoa.jpg)

**Table 4c**

**Factors Affecting Segment Net Sales Year Over Year - Unaudited**

**Year Ended December 31, 2025 Compared to Year Ended December 31, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (4) | (1) | 1 | (4) |
| Acetyl Chain | (6) | (6) | 1 | (11) |
| **Total Company** | (4) | (4) | 1 | (7) |

---

**Year Ended December 31, 2024 Compared to Year Ended December 31, 2023**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Volume** | **Price** | **Currency** | **Total** |
| | **(In percentages)** | **(In percentages)** | **(In percentages)** | **(In percentages)** |
| Engineered Materials | (5) | (3) | (1) | (9) |
| Acetyl Chain | 4 | (6) |  | (2) |
| **Total Company** | (1) | (4) | (1) | (6) |

---

------

![celogoa.jpg](celogoa.jpg)

**Table 5**

**Free Cash Flow - Reconciliation of a Non-GAAP Measure - Unaudited**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | **Q3 '25** | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | **Q3 '24** | **Q2 '24** | **Q1 '24** |
| | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** |
| Net cash provided by (used in) investing activities | (349) | (104) | (59) | (88) | (98) | (470) | (128) | (100) | (91) | (151) |
| Net cash provided by (used in) financing activities | (513) | (324) | (118) | (116) | 45 | (1313) | (189) | (376) | (489) | (259) |
| Net cash provided by (used in) operating activities | 1146 | 252 | 447 | 410 | 37 | 966 | 494 | 79 | 292 | 101 |
| Capital expenditures on property, plant and equipment | (343) | (84) | (64) | (93) | (102) | (435) | (105) | (88) | (105) | (137) |
| Contributions from/(Distributions) to NCI | (30) | (8) | (8) | (6) | (8) | (33) | (8) | (7) | (14) | (4) |
| &nbsp;&nbsp;**Free cash flow**<sup>(1)</sup> | 773 | 160 | 375 | 311 | (73) | 498 | 381 | (16) | 173 | (40) |
| Net sales | 9544 | 2204 | 2419 | 2532 | 2389 | 10268 | 2358 | 2648 | 2651 | 2611 |
| **Free cash flow as % of Net sales** | 8.1% | 7.3% | 15.5% | 12.3% | (3.1)% | 4.9% | 16.2% | (0.6)% | 6.5% | (1.5)% |

---

______________________________

<sup>(1)</sup> Free cash flow is a liquidity measure used by the Company and is defined by the Company as net cash provided by (used in) operating activities, less capital expenditures on property, plant and equipment, and adjusted for contributions from or distributions to our NCI joint ventures.

------

![celogoa.jpg](celogoa.jpg)

**Table 6**

**Cash Dividends Received - Unaudited**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | **Q3 '25** | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | **Q3 '24** | **Q2 '24** | **Q1 '24** |
| | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** |
| Dividends from equity method investments | 139 | 47 | 40 | 21 | 31 | 160 | 38 | 26 | 69 | 27 |
| Dividends from equity investments without readily determinable fair values | 122 | 40 | 40 | 41 | 1 | 128 | 33 | 30 | 31 | 34 |
| &nbsp;&nbsp;&nbsp;**Total** | 261 | 87 | 80 | 62 | 32 | 288 | 71 | 56 | 100 | 61 |

---

**Table 7**

**Net Debt - Reconciliation of a Non-GAAP Measure - Unaudited**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | **Q3 '25** | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | **Q3 '24** | **Q2 '24** | **Q1 '24** |
| | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** |
| Short-term borrowings and current installments of long-term debt - third party and affiliates | 1204 | 1204 | 1199 | 252 | 406 | 1501 | 1501 | 1607 | 1977 | 2439 |
| Long-term debt, net of unamortized deferred financing costs | 11394 | 11394 | 11655 | 12689 | 12378 | 11078 | 11078 | 11324 | 11058 | 11018 |
| &nbsp;&nbsp;&nbsp;Total debt | 12598 | 12598 | 12854 | 12941 | 12784 | 12579 | 12579 | 12931 | 13035 | 13457 |
| Cash and cash equivalents | (1263) | (1263) | (1440) | (1173) | (951) | (962) | (962) | (813) | (1185) | (1483) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net debt** | 11335 | 11335 | 11414 | 11768 | 11833 | 11617 | 11617 | 12118 | 11850 | 11974 |

---

------

![celogoa.jpg](celogoa.jpg)

**Table 8**

**Certain Items - Unaudited**

The following Certain Items attributable to Celanese Corporation are included in Net earnings (loss) and are adjustments to non-GAAP measures:

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **2025** | **Q4 '25** | | **Q3 '25** | | **Q2 '25** | **Q1 '25** | **2024** | **Q4 '24** | | **Q3 '24** | | **Q2 '24** | **Q1 '24** | **Income Statement Classification** |
| | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | **(In $ millions)** | |
| Exit and shutdown costs | 98 | 29 |  | 10 |  | 27 | 32 | 236 | 47 |  | 52 |  | 69 | 68 | Cost of sales / SG&A / Other (charges) gains, net / Gain (loss) on disposition of businesses and assets, net / Non-operating pension and other postretirement employee benefit (expense) income |
| Asset impairments | 1513 | 27 | (1) | 1486 | (2) |  |  | 1638 | 1601 | (3) | 34 | (4) | 3 |  | Cost of sales / Other (charges) gains, net |
| Impact from plant incidents and natural disasters | 3 |  |  |  |  |  | 3 | 13 | 3 |  | 3 |  |  | 7 | Cost of sales |
| Mergers, acquisitions and dispositions | 52 | 23 |  | 12 |  | 12 | 5 | 80 | 12 |  | 17 |  | 26 | 25 | Cost of sales / SG&A |
| Actuarial (gain) loss on pension and postretirement plans | (49) | (49) |  |  |  |  |  | 27 | 27 |  |  |  |  |  | Cost of sales / SG&A / Non-operating pension and other postretirement employee benefit (expense) income |
| Legal settlements and commercial disputes | 17 | 1 |  | 11 |  | 2 | 3 | 8 | 6 |  | 7 |  | 3 | (8) | Cost of sales / SG&A / Other (charges) gains, net |
| (Gain) loss on disposition of businesses and assets |  |  |  |  |  |  |  | 2 |  |  | 1 |  | 1 |  | Gain (loss) on disposition of businesses and assets, net |
| Other | 5 | 3 |  | 1 |  | 1 |  | 5 |  |  |  |  |  | 5 | Cost of sales / SG&A |
| &nbsp;&nbsp;&nbsp;&nbsp;**Certain Items attributable to Celanese Corporation** | 1639 | 34 |  | 1520 |  | 42 | 43 | 2009 | 1696 |  | 114 |  | 102 | 97 |  |

---

___________________________

<sup>(1)</sup> Related to impairment of certain long-lived assets arising from unused parcels of property subsequently sold.

<sup>(2)</sup> Related to impairment of goodwill and certain trade names, primarily Zytel<sup>®</sup>, arising from our annual goodwill and indefinite-lived intangible assets impairment tests.

<sup>(3)</sup> Related to impairment of goodwill and certain trade names, primarily Zytel<sup>®</sup>, arising from our interim goodwill and indefinite-lived intangible assets impairment tests.

<sup>(4)</sup> Related to impairment of certain trade names, primarily Zytel<sup>®</sup>, in connection with our annual goodwill and indefinite-lived intangible asset impairment tests.

------

![celogoa.jpg](celogoa.jpg)

**Table 9**

**Return on Invested Capital (Adjusted) - Presentation of a Non-GAAP Measure - Unaudited**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | **2025** | | | **2024** |
| | | | **(In $ millions, except percentages)** | | | **(In $ millions, except percentages)** |
| Net earnings (loss) attributable to Celanese Corporation |  |  | (1165) |  |  | (1542) |
| Adjusted EBIT (<u>[Table 1](#i314c3b6c9ca9490fbb2137b9416a9e51_7)</u>) |  |  | 1150 |  |  | 1625 |
| Adjusted effective tax rate (<u>[Table 3a](#i314c3b6c9ca9490fbb2137b9416a9e51_22)</u>) |  |  | 8% |  |  | 9% |
| &nbsp;&nbsp;&nbsp;Adjusted EBIT tax effected |  |  | 1058 |  |  | 1479 |
|  | **2025** | **2024** | **Average** | **2024** | **2023** | **Average** |
|  | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** | **(In $ millions, except percentages)** |
| Short-term borrowings and current installments of long-term debt - third parties and affiliates | 1204 | 1501 | 1353 | 1501 | 1383 | 1442 |
| Long-term debt, net of unamortized deferred financing costs | 11394 | 11078 | 11236 | 11078 | 12301 | 11690 |
| Celanese Corporation shareholders' equity | 4049 | 5129 | 4589 | 5129 | 7065 | 6097 |
| &nbsp;&nbsp;&nbsp;Invested capital |  |  | 17178 |  |  | 19229 |
| **Return on invested capital (adjusted)** |  |  | 6.2% |  |  | 7.7% |
| **Net earnings (loss) attributable to Celanese Corporation as a percentage of invested capital** |  |  | (6.8)% |  |  | (8.0)% |

---